Bell Michael A, Campbell Jeffrey D, Joice Gregory, Sopko Nikolai A, Burnett Arthur L
The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
World J Mens Health. 2018 May;36(2):103-109. doi: 10.5534/wjmh.170007. Epub 2018 Mar 22.
Historically, testosterone and prostate cancer have been demonstrated to have a positive association leading providers to forgo testosterone replacement therapy (TRT) in men with concurrent histories of hypogonadism and prostate cancer. This paradigm has been gradually shifting with our evolving understanding of the relationship between testosterone and prostate cancer and the gaining popularity of the saturation model. Newer data suggests improved quality of life for men with hypogonadism after TRT leading to a more tempered view of the effects of this treatment and its risk in prostate cancer. As more reports emerge of TRT in men who have either undergone definitive treatment for prostate cancer or are on active surveillance, some providers see a role for TRT in these patients despite non-consensus in clinical guidelines. It is critical that we examine evidence currently available, while we await more rigorous data to emerge.
从历史上看，睾酮与前列腺癌之间已被证明存在正相关关系，这使得医疗服务提供者在患有性腺功能减退和前列腺癌并存病史的男性中放弃睾酮替代疗法（TRT）。随着我们对睾酮与前列腺癌之间关系的不断深入理解以及饱和模型的日益流行，这种模式已逐渐转变。最新数据表明，接受TRT的性腺功能减退男性的生活质量有所改善，从而使人们对这种治疗的效果及其在前列腺癌中的风险有了更为缓和的看法。随着越来越多关于已接受前列腺癌根治性治疗或正在接受积极监测的男性进行TRT的报告出现，尽管临床指南尚未达成共识，但一些医疗服务提供者认为TRT在这些患者中具有一定作用。在等待更严格的数据出现的同时，审视目前可用的证据至关重要。
